A case of bullous dermatitis induced by erlotinib

Alessandro Oteri; Maria Teresa Cattaneo; Virginio Filipazzi; Sabrina Ferrario; Anna Gambaro; Luigi Isabella; Nicoletta Tosca; Emilio Clementi; Sonia Radice; Elena Piazza

doi:10.1634/theoncologist.2009-0118

A case of bullous dermatitis induced by erlotinib

Alessandro Oteri, Maria Teresa Cattaneo, Virginio Filipazzi, Sabrina Ferrario, Anna Gambaro, Luigi Isabella, Nicoletta Tosca, Emilio Clementi, Sonia Radice, Elena Piazza

Istituto "Eugenio Medea" - Associazione La Nostra Famiglia

Research output: Contribution to journal › Article › peer-review

Abstract

Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.

Original language	English
Pages (from-to)	1201-1204
Number of pages	4
Journal	The oncologist
Volume	14
Issue number	12
DOIs	https://doi.org/10.1634/theoncologist.2009-0118
Publication status	Published - 2009

Keywords

Bullous dermatitis
Case report
Erlotinib
Skin toxicity

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1634/theoncologist.2009-0118

Cite this

@article{aecd147d1c534230aae8b786ba87143d,

title = "A case of bullous dermatitis induced by erlotinib",

abstract = "Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.",

keywords = "Bullous dermatitis, Case report, Erlotinib, Skin toxicity",

author = "Alessandro Oteri and Cattaneo, {Maria Teresa} and Virginio Filipazzi and Sabrina Ferrario and Anna Gambaro and Luigi Isabella and Nicoletta Tosca and Emilio Clementi and Sonia Radice and Elena Piazza",

year = "2009",

doi = "10.1634/theoncologist.2009-0118",

language = "English",

volume = "14",

pages = "1201--1204",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Wiley Blackwell",

number = "12",

}

TY - JOUR

T1 - A case of bullous dermatitis induced by erlotinib

AU - Oteri, Alessandro

AU - Cattaneo, Maria Teresa

AU - Filipazzi, Virginio

AU - Ferrario, Sabrina

AU - Gambaro, Anna

AU - Isabella, Luigi

AU - Tosca, Nicoletta

AU - Clementi, Emilio

AU - Radice, Sonia

AU - Piazza, Elena

PY - 2009

Y1 - 2009

N2 - Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.

AB - Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.

KW - Bullous dermatitis

KW - Case report

KW - Erlotinib

KW - Skin toxicity

UR - http://www.scopus.com/inward/record.url?scp=75449101845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449101845&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2009-0118

DO - 10.1634/theoncologist.2009-0118

M3 - Article

C2 - 19965913

AN - SCOPUS:75449101845

VL - 14

SP - 1201

EP - 1204

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -

A case of bullous dermatitis induced by erlotinib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this